HealthNovartis Drug Lowers Annualized Relapse Rates by Up to 35.2% in MS TrialsBy Naomi CalderOct 24, 2026, 2:44 AM UTC
BusinessAXIM Biotech Secures Additional Funding to Advance Cannabidnoid-Based Clinical Development Program for Multiple IndicationsBy Nasdaq OMXApr 23, 2018, 1:00 PM UTC
BusinessAXIM Biotech Reaches Preliminary Agreement for Distribution of CanChew and MedChew Products Throughout South KoreaBy Nasdaq OMXApr 3, 2018, 1:02 PM UTC
BusinessAdamas Announces First Patient Enrolled in Phase 3 Trial of ADS-5102 in Multiple Sclerosis Patients with Walking ImpairmentBy Nasdaq OMXApr 3, 2018, 1:02 PM UTC
BusinessAdamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2017By Nasdaq OMXFeb 22, 2018, 9:01 PM UTC
BusinessNutra Pharma Files Provisional Patent for Nerve Agent Counter MeasuresBy Nasdaq OMXFeb 21, 2018, 1:31 PM UTC
BusinessAdamas Announces Publication of ADS-5102 Phase 2 Clinical Trial Results in Multiple Sclerosis JournalBy Nasdaq OMXFeb 1, 2018, 9:05 PM UTC
BusinessAXIM Biotech Announces Successful Completion of Exploratory Meeting with the Dutch Medicines Evaluation Board on MedChew Rx Program for Treatment of Pain and Spasticity in MS PatientsBy Nasdaq OMXJan 23, 2018, 2:02 PM UTC
